Norgine ends investment in Internis Pharmaceuticals

Norgine has announced that it has successfully exited its investment in Internis Pharmaceuticals, which it has been supporting financially for two years.

The relationship between Internis and Norgine Ventures has come to an end following Internis' acquisition by an undisclosed pharmaceutical company in December 2014. Both companies have hailed the positive impact the funding arrangement has provided.

Founded in 2010, Internis launched Fultium D3, its first fully licensed prescription vitamin D3 oral product, in the UK in 2012. With Norgine's assistance, the firm has been able to accelerate its commercial development efforts and new product development programme.

Since launch, Fultium D3 has become a leading brand within its category, helping Internis to experience rapid growth. The firm has now thanked Norgine for its support during this formative period.

Charles Tannenbaum, former joint chief executive officer of Internis, said: "Their investment, support and belief in our company and products has enabled us to achieve our growth potential and realise significant value creation in a short period of time."

Employing more than 1,000 people worldwide, Norgine is headquartered in the Netherlands and bases its global operations in Amsterdam and Harefield in the UK.